Keybank National Association OH Boosts Holdings in AbbVie Inc. $ABBV

Key Points

• KeyBank National Association OH modestly increased its stake in AbbVie by 0.8% to 1,053,057 shares (about $240.6M), and roughly 70.2% of ABBV is currently held by hedge funds and other institutional investors.
• AbbVie reported several pipeline catalysts — FDA applications for RINVOQ (alopecia areata) and SKYRIZI (Crohn’s), positive SELECT‑SWITCH data showing RINVOQ beat HUMIRA, and an option to acquire Kestrel — but also received a CRL for trenibotulinumtoxinE, presenting mixed regulatory outcomes.
• Corporate insiders sold a combined ~27,611 shares in recent transactions, AbbVie declared a quarterly dividend of $1.73 per share (annualized yield ~3.5%), and Q1 earnings/guidance could drive near‑term stock volatility.

Keybank National Association OH boosted its position in AbbVie Inc. (NYSE:ABBV - Free Report) by 0.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,053,057 shares of the company's stock after buying an additional 8,229 shares during the period. AbbVie makes up about 0.9% of Keybank National Association OH's holdings, making the stock its 22nd biggest position. Keybank National Association OH owned approximately 0.06% of AbbVie worth $240,613,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ABBV. Brighton Jones LLC grew its position in AbbVie by 17.4% in the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company's stock valued at $4,072,000 after buying an additional 3,401 shares during the last quarter. Revolve Wealth Partners LLC grew its position in AbbVie by 72.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company's stock valued at $1,294,000 after buying an additional 3,064 shares during the last quarter. Schnieders Capital Management LLC. grew its position in AbbVie by 5.0% in the 2nd quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company's stock valued at $3,056,000 after buying an additional 789 shares during the last quarter. Ieq Capital LLC grew its position in AbbVie by 4.6% in the 2nd quarter. Ieq Capital LLC now owns 120,035 shares of the company's stock valued at $22,281,000 after buying an additional 5,274 shares during the last quarter. Finally, Worldquant Millennium Advisors LLC grew its position in AbbVie by 117.3% in the 2nd quarter. Worldquant Millennium Advisors LLC now owns 1,135,034 shares of the company's stock valued at $210,685,000 after buying an additional 612,702 shares during the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at AbbVie

In other news, SVP David Ryan Purdue sold 5,230 shares of the company's stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the transaction, the senior vice president owned 2,654 shares of the company's stock, valued at $619,868.24. This represents a 66.34% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Perry C. Siatis sold 22,381 shares of the company's stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the transaction, the executive vice president directly owned 38,137 shares of the company's stock, valued at approximately $8,771,510. This represents a 36.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.06% of the company's stock.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie filed a U.S. FDA application to expand RINVOQ (upadacitinib) to treat adults and adolescents with severe alopecia areata — a new label that could add incremental sales if approved. AbbVie Submits Application to FDA for Upadacitinib (RINVOQ) for Adults and Adolescents with Severe Alopecia Areata
• Positive Sentiment: AbbVie submitted an FDA application to expand SKYRIZI (risankizumab‑rzaa) subcutaneous induction for Crohn’s disease — another label expansion that, if approved, supports Skyrizi’s growth profile. AbbVie Submits Regulatory Application to FDA for SKYRIZI (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease
• Positive Sentiment: Topline SELECT‑SWITCH Phase 3b/4 data show RINVOQ (upadacitinib) beat HUMIRA on the primary endpoint in RA patients who failed a TNF inhibitor — supportive clinical data for market share gains. RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study
• Positive Sentiment: AbbVie secured an option/warrant arrangement with Kestrel (KRAS inhibitor) and may acquire the company for up to $1.45B as Kestrel advances its pan‑KRAS program — strengthens oncology pipeline exposure. AbbVie sinks talons into KRAS with right to buy Kestrel for up to $1.45B
• Positive Sentiment: Kestrel announced first patient dosed in its Phase 1 pan‑KRAS trial; the program is tied to AbbVie’s option — clinical progress that could trigger future deal milestones. Kestrel Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of KST-6051
• Positive Sentiment: EvolveImmune announced a preclinical milestone in a collaboration with AbbVie, triggering an $18M payment — validates external partnership model and de‑risks some immuno‑oncology work. EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie
• Neutral Sentiment: AbbVie is due to report Q1 earnings tomorrow; previews expect Skyrizi and RINVOQ to drive recovery — near‑term volatility possible around results. AbbVie (ABBV) To Report Earnings Tomorrow: Here Is What To Expect
• Neutral Sentiment: Market pieces are re‑assessing AbbVie’s valuation after recent share softness vs longer‑term gains — useful context but not an immediate catalyst. Assessing AbbVie (ABBV) Valuation After Recent Share Price Softness And Long Term Gains
• Negative Sentiment: A small biotech’s experimental psoriasis drug (Oruka) produced ~two‑thirds complete clearance in trials — a direct competitive threat to AbbVie’s large psoriasis franchise (~$18B) and a key reason for investor nerves. How A Small Biotech Name Just Rattled AbbVie's $18 Billion Franchise
• Negative Sentiment: The FDA issued a Complete Response Letter (CRL) for AbbVie’s trenibotulinumtoxinE biologics license application — a regulatory setback that delays or jeopardizes a product launch. AbbVie Inc. (ABBV) Receives CRL from the FDA About the Biologics License Application for trenibotulinumtoxinE

AbbVie Trading Up 0.2%

Shares of ABBV stock opened at $197.84 on Wednesday. The firm has a 50-day moving average price of $215.29 and a 200 day moving average price of $221.79. AbbVie Inc. has a twelve month low of $176.57 and a twelve month high of $244.81. The company has a market capitalization of $349.81 billion, a price-to-earnings ratio of 83.83, a PEG ratio of 0.71 and a beta of 0.38.

AbbVie (NYSE:ABBV - Get Free Report) last announced its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The firm had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. During the same quarter in the previous year, the company posted $2.16 EPS. The firm's revenue for the quarter was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, research analysts predict that AbbVie Inc. will post 14.21 earnings per share for the current year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.5%. AbbVie's dividend payout ratio is currently 293.22%.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on ABBV shares. Piper Sandler decreased their target price on shares of AbbVie from $299.00 to $294.00 and set an "overweight" rating on the stock in a research report on Thursday, April 23rd. UBS Group decreased their target price on shares of AbbVie from $240.00 to $230.00 and set a "neutral" rating on the stock in a research report on Thursday, February 5th. Royal Bank Of Canada started coverage on shares of AbbVie in a research report on Tuesday, February 24th. They set an "outperform" rating and a $260.00 target price on the stock. Guggenheim boosted their target price on shares of AbbVie from $242.00 to $249.00 and gave the stock a "buy" rating in a research report on Friday, April 10th. Finally, BMO Capital Markets restated an "outperform" rating on shares of AbbVie in a research report on Monday, March 9th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $253.19.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.